The Pharma Data

SEPTEMBER 3, 2020

Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Source link.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). These results demonstrate that MS DMTs impact antibody responses to COVID-19 vaccination in different ways and understanding these differences is crucial,” said Jeffrey Cohen, M.D.,

Vaccine 52

Vaccine Therapies Disease Immune Response 52

Drug Target Review

JANUARY 15, 2024

Antibodies in general cannot cross the plasma membrane or direct responses against intracellular targets, whereas many critical steps in oncogenesis and tumour pathology occur inside the cell, concealed from the protective effects of antibodies. Many potential candidate antigens are under consideration.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

SEPTEMBER 8, 2023

However, recent insights indicate that it also operates beyond the nucleus, orchestrating initial events at the cell surface that trigger the activation of T cells. Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

JANUARY 31, 2021

Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Investigators aim to have initial findings available by August 2022.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Alta Sciences

JANUARY 11, 2024

It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. However, there are significant challenges associated with the successful development of these complex, leading-edge therapies.

Therapies 52

Therapies Immune Response Disease Virus 52

The Pharma Data

OCTOBER 9, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% 100) against moderate or severe disease. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 10, 2020

P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Oral and nasal administration routes are both physiologic approaches to stimulate the mucosal immune system to induce disease modifying benefits.”.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

Codon

JULY 14, 2024

In contrast, people with sickle cell disease commonly receive red blood cell transfusions to alleviate vaso-occlusive pain crises. 2 And while transfusions are among the safest procedures in medicine, there is still a very slight risk of transmission of infectious diseases and adverse immune reactions. In the U.S.,

Production 133

Production Clinical Trials Trials Therapies 133

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Diseased cells are likely to be more fragile or less abundant, making it difficult to obtain enough for therapy.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

JANUARY 5, 2021

.” The clinical trial involved 24 COVID patients at one of two Miami-area hospitals who had developed severe acute respiratory distress syndrome, a condition in which the body’s immune response to a serious infection causes the lungs to fill with fluid.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

NOVEMBER 9, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Data from the event-driven trial could support global authorization and approval, including in the U.S. GAITHERSBURG, Md., 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. and globally.”.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 11, 2020

. “They will be asked to stand in line and get a vaccine also,” said Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center in Nashville, Tenn. ” Coronaviruses are notorious for prompting a flawed and incomplete immune response in humans, infectious disease experts say. .

Vaccine 52

Vaccine Immune Response Virus Trials 52

Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

The Pharma Data

MARCH 8, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Canakinumab is a first-in-class interleukin-1beta (IL-1?) 2 mg/L) 8,9. million new cases each year 11 , 1 3.?Currently,

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

The Pharma Data

DECEMBER 8, 2020

In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. There was also no mention of any adverse events or side effects that are common with vaccinations, such as soreness in the arm where the shot was administered.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

MARCH 9, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Canakinumab is a first-in-class interleukin-1beta (IL-1?) 2 mg/L) 8,9. million new cases each year 11 , 1 3.?Currently,

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 3 The European Centre for Disease Prevention and Control (ECDC) currently recommends TBE vaccination for people who live in or are traveling to risk areas.

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. No serious adverse events related to the vaccine candidates studied were reported. CHENGDU, China , Feb. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

APRIL 11, 2021

Additionally, Opdivo plus chemotherapy was well tolerated and showed consistent improvements in pCR regardless of PD-L1 expression levels, histologies or stages of disease. The ultimate goal of treatment in earlier stages of cancer is to prevent the disease from coming back as we work towards a cure for these patients.

Trials 52

Trials Treatment Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. . Through week 8, no serious adverse events were reported.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

JANUARY 11, 2021

Stephane Bancel, chief executive officer of Moderna , speaking at a virtual event by Oddo BHF, a financial service group, said, “We believe there will be protection potentially for a couple of years.” . Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. A study published by the U.S.

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

SEPTEMBER 10, 2021

This treatment combination also reduced the risk of disease progression or death by 28% compared to chemotherapy alone (HR 0.72; 95% CI 0.60-0.86; Number of patients with event (%) 3. Number of patients with event (%) 5. Grade 3 or 4 treatment-related adverse events were experienced by 51.8% Median OS was 14.0

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 28, 2020

. Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease.

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Interim data in this event-driven trial are expected as soon as early first quarter 2021, although the timing depends on the overall COVID-19 rate in the region.

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

JANUARY 17, 2021

People living with LN are in need of an advanced therapy that quickly drives the disease into remission and mediates kidney damage,” said Peter Greenleaf, president and chief executive officer of Aurinia, in July 2020 when the FDA accepted the NDA to review. “We HFrEF was formerly known as systolic heart failure.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., In the overall trial population, the incidence of serious adverse events was 21% for high dose, 20% for low dose and 24% for placebo. cardiovascular disease, OR. sickle cell disease, OR.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 17, 2020

In the initial 275 patients, rates of adverse events (AEs) were similar among groups. Have chronic kidney disease. Have immunosuppressive disease. cardiovascular disease, OR. chronic obstructive pulmonary disease/other chronic respiratory disease. sickle cell disease, OR. The event resolved.

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

The Pharma Data

OCTOBER 25, 2020

The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 µg dose level in the U.S.

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52